Skip to main content

Table 2 Correlation of SOX2 score and clinicopathological parameters

From: Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma

   SOX2  
  N total Negative Score 0 Positive Score 1-3 p-value
Tumor size     
   pT1 59 46 (78%) 13 (22%) 0.073
   pT2 to pT4 27 16 (59%) 11 (41%)  
Nodal status     
   Node-negative 62 44 (71%) 18 (29%) 0.789
   Node-positive 23 17 (74%) 6 (26%)  
Histology     
   Ductal 76 49 (73%) 18 (27%)  
   Lobular 11 10 (91%) 1 (10%) 0.053
   Others 8 5 (38%) 5 (63%)  
Grading     
   I-II 60 45 (75%) 15 (25%) 0.361
   III 26 17 (65%) 9 (35%)  
Lymphovasc. inv.     
   Negative 63 48 (76%) 15 (24%) 0.161
   Positive 23 14 (61%) 9 (39%)  
ER status     
   Negative 17 12 (71%) 5 (29%) 0.877
   Positive 69 50 (73%) 19 (28%)  
PR status     
   Negative 22 16 (73%) 6 (27%) 0.939
   Positive 64 46 (72%) 18 (28%)  
HER2     
   Negative 75 55 (73%) 20 (27%) 0.503
   Positive 11 7 (64%) 4 (36%)  
Subtype     
   Luminal A/B * 73 53 (73%) 20 (27%)  
   HER2 subtype 6 4 (67%) 2 (33%) 0.952
   Triple negative 7 5 (71%) 2 (29%)  
  1. *Luminal A tumors are defined as tumors with expression of one or both hormone receptors without overexpression of Her2; Luminal B tumors express one or both hormone receptors and show also Her2 overexpression.